Tag: Abbott
Abbott launches Liberta RC deep brain stimulation system with remote programming...
Abbott recently announced that it has received approval from the US Food and Drug Administration (FDA) to launch the Liberta RC deep brain stimulation...
Abbott gains expanded MRI labelling from US FDA for Proclaim DRG...
Abbott has announced that the US Food and Drug Administration (FDA) has approved expanded magnetic resonance imaging (MRI) labelling for its dorsal root ganglion...
Abbott gains US FDA nod to treat non-surgical back pain with...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic...
Abbott announces expanded MRI labelling for Eterna spinal cord stimulation system
Abbott has announced that the US Food and Drug Administration (FDA) has approved expanded magnetic resonance imaging (MRI) labelling for its Eterna spinal cord...
Abbott gains US FDA approval for SCS therapy in painful diabetic...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful...
Abbott presents new data on streamlining patient-reported measures, BurstDR and more...
Abbott presented new data in more than 30 presentations and posters at the North American Neuromodulation Society (NANS) annual meeting (12–15 January 2023, Las...
Abbott launches “world’s smallest” implantable, rechargeable SCS system for chronic pain
Abbott has announced the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is...
Abbott to receive multiple CES 2023 awards for neurostimulation and pacemaker...
Abbott has been recognised by the Consumer Technology Association (CTA) with three Consumer Electronics Show (CES 2023; 5–8 January, Las Vegas, USA) Innovation Awards...
New CMS telehealth designation extends coverage of Abbott’s NeuroSphere virtual clinic
As part of its Medicare Telehealth Services List, the US Centers for Medicare and Medicaid Services (CMS) will continue to cover the use of...
Abbott gains US FDA approval for Proclaim Plus spinal cord stimulation...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360...
Abbott introduces Canada’s first remote neuromodulation patient-care technology
Abbott recently announced the Health Canada licensing of NeuroSphere virtual clinic, a remote programming technology that the company claims is the first of its kind...
Abbott receives Breakthrough Device designation to explore DBS in managing severe...
Abbott recently announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to investigate the use of its deep brain...
Abbott upgrades NeuroSphere myPath app for patient monitoring in neuromodulation trials
Abbott today announced that it has launched an upgraded version of its NeuroSphere myPath digital health app with enhanced functionality intended to help doctors...
Updated medical policy expands patient access to Abbott’s DRG stimulation technology
Abbott announced today that UnitedHealthcare (UHC)—the largest private health insurance company in the USA—has updated its ‘Implanted electrical stimulator for spinal cord’ medical policy...
Abbott announces expanded MRI compatibility for Proclaim XR spinal cord stimulation...
Abbott has announced that the US Food and Drug Administration (FDA) has approved new, expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord...
Passive recharge burst SCS provides sustainable improvements in pain and psychosocial...
Passive recharge burst spinal cord stimulation (B-SCS) can alleviate pain intensity and psychological distress, and improve physical function and health-related quality of life out...
CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...
The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...
Abbott announces NeuroSphere Virtual Clinic
Abbott has announced the US launch of its NeuroSphere Virtual Clinical, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings...
Abbott announces the US launch of their IonicRF device
Abbott has announced that their IonicRF, a minimally invasive radiofrequency ablation device, is now being launched in the USA. This is after the IonicRF...
FDA approves Abbott’s iOS-compatible app for the management of chronic pain...
Abbott announces it has received approval from the US Food and Drug Administration (FDA) for the use of its Patient Controller app on compatible...
Abbott receives expanded indication from FDA for directional DBS to treat...
Abbott has announced it received approval from the US Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity deep...
News from NANS: BurstDR stimulation reduces negative psychological effects associated with...
New quality of life and functional improvement data from both the BOLD and TRIUMP studies echo the benefits of the Proclaim XR neurostimulation system...
FDA approves low-dose spinal cord stimulator for chronic pain
Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...
New study finds Abbott’s blood test technology could help detect brain...
Abbott has announced that a new study, published in Lancet Neurology, found that elevated levels of a protein measured with the company's blood test...
Abbott partners with NIH on BRAIN initiative to advance research for...
Abbott have announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative...
Burst stimulation of the spinal cord leads to greater pain modulation...
Data from a substudy of SUNBURST suggest that burst stimulation of the spinal cord regulates the medial pain pathway to a greater extent than...
New data show the therapeutic benefits of directional leads for use...
The PROGRESS study has achieved its primary endpoint and demonstrated superiority of the therapeutic window using Abbott directional stimulation compared to omnidirectional stimulation. Results...
Abbott receives CE mark of MR-conditional labelling for Infinity deep brain...
Parkinson’s disease, dystonia and essential tremor patients in CE Mark countries will now benefit from upgraded functionality and new magnetic resonance (MR) conditional labelling...
Positive data for BurstDR spinal cord stimulation
New results from a multicentre study of Abbott’s BurstDR stimulation show that lower-energy, intermittent doses of BurstDR stimulation—known as “microdosing”—can provide pain relief that is...
New approvals allow chronic pain sufferers to try Abbott’s non-opioid pain...
Abbott has announced the launch of the new dorsal root ganglion (DRG) Invisible Trial System, which is approved by the US Food and Drug...
Coverage decision extends DRG therapy to 22 million Americans living with...
Abbott has announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna. With this coverage decision,...
Abbott expands its directional deep brain stimulation therapy by offering new...
Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity DBS system. Abbott has announced US Food and Drug...
Evidence in favour of DRG stimulation builds with real-world data
The real-world data collected in the PREDICT study has added to the evidence in favour of dorsal root ganglion (DRG) stimulation for the management...
Spinal cord stimulation reduces or stabilises opioid use among chronic pain...
New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...
Proclaim DRG Neurostimulation System introduced in Europe
Abbott has announced the European launch of the new Proclaim DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering...
ACCURATE 12-month data published in Pain
New data published in the January edition of Pain has confirmed the superiority of dorsal root ganglion (DRG) stimulation therapy (from Abbott) over traditional...
Abbott completes the acquisition of St Jude Medical
Abbott has now completed the acquisition of St Jude Medical. The Abbott press release announcing the completion of the acquisition said, “The transaction provides...
